Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
2(14%)
Results Posted
80%(8 trials)

Phase Distribution

Ph phase_1
2
14%
Ph phase_2
6
43%
Ph phase_4
2
14%
Ph phase_3
1
7%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(10)
Terminated(1)
Other(1)

Detailed Status

Completed10
Active, not recruiting1
Recruiting1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 26 (54.5%)
Phase 31 (9.1%)
Phase 42 (18.2%)

Trials by Status

completed1071%
active_not_recruiting17%
recruiting17%
withdrawn17%
unknown17%

Recent Activity

2 active trials
Showing 5 of 14
active_not_recruitingphase_3

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372
recruiting

A Prospective Sub-Study of the Global Hypophosphatasia Registry

NCT05234567
completed

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

NCT04195763
withdrawnphase_4

Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease

NCT04189315
completedphase_2

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

NCT02797821
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06079372Phase 3

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Active Not Recruiting
NCT05234567

A Prospective Sub-Study of the Global Hypophosphatasia Registry

Recruiting
NCT04195763

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

Completed
NCT04189315Phase 4

Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease

Withdrawn
NCT02797821Phase 2

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

Completed
NCT00744042Phase 1

Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

Completed
NCT00952484Phase 2

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Completed
NCT02496689

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

Unknown
NCT00739505Phase 1

Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)

Completed
NCT01176266Phase 2

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Completed
NCT01205152Phase 2

Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Completed
NCT01163149Phase 2

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

Completed
NCT01203826Phase 2

Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)

Completed
NCT02531867Phase 4

Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14